

Corporate Office :  
406, Silver Oaks Comm. Complex,  
Opp. Arun Society, Paldi,  
Ahmedabad-380 007. Gujarat, India.  
Phone : 079-26584655  
Fax : 079-26588054  
CIN No. : L24231GJ2004PLC043861  
E-mail : info@sakarhealthcare.com  
Web : www.sakarhealthcare.com

**Date: 16<sup>th</sup> July, 2025**

To  
The Manager  
Listing Compliance Department  
National Stock Exchange of India Ltd.  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E), Mumbai-400051, India

Symbol: SAKAR

**SUB: SAKAR granted with THIRD & FOURTH Marketing Authorization (MA)/ Registration of ONCOLOGY INJECTIONS in EUROPE**

Dear All,

There has been two more Marketing Authorisations (MA) granted with oncology injection (product registration) to Sakar in the European Union, taking the count to four MAs.

Two of the product dossiers for Carboplatin and Docetaxel compiled under EU guidelines have fetched approvals from Bulgaria and Bosnia. Both the dossiers are a part of Sakar's present effort in regulatory front from its research-driven API-integrated EU GMP approved oncology formulation manufacturing unit.

While the earlier products (MAs) intends to treating breast cancer, non-small cell lung cancer, prostate cancer, colorectal cancer; Carboplatin is intended for ovarian, lung cancer along with other solid tumours. Strategically these approvals now widens the scope to export anti-cancer injections to the European countries, while Sakar prepares the commercial supply with the first two received MAs.

With a mix of oncology products in process of registration in the EU and rest of world markets, Sakar expects to receive grant of more MAs within few months. These MAs will speed up the export of multiple oncology products to the EU region manufactured at Sakar's state-of-the-art vertically integrated oncology product manufacturing site.

Thanking you for the encouragement.

Yours faithfully,  
FOR, SAKAR HEALTHCARE LIMITED

BHARAT SONI  
COMPANY SECRETARY AND  
COMPLIANCE OFFICER